AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Zenitas Healthcare (ASX: ZNT ) shares sky-rocketed 22.51% to $1.415 (31 August 2018; 1:50 PM AEST) on the release of scheme implementation deed announcing 100% of the Zenitas acquisition by Adamantem Capital and Liverpool Partners consortium for $1.46 per share in cash.
The company also released its annual results for the full year to 30 June 2018, posting $54.2 million increase in revenue to $76.6 million, driven by contribution received from recent acquisitions.
[optin-monster-shortcode id="wxhmli4jjedneglg1trq"]
The healthcare company has completed 13 acquisitions of community-based healthcare businesses, underpinned by $30 million capital raised in November 2017. Peninsula Sports Medicine Group, Agewell, Beleura and Australian Home Care and Orion services have been the major acquisitions made this year.
Underlying NPAT has gone up by 78% to $5.7 million on the back of benefits derived from expansion of business with 20 more clinics and over 55,000+ new client base. Groupâs underlying EBITDA increased to $13.9 million, up $6.9 million, excluding one-off acquisition cost of $1.86 million. Reported EPS slipped to 6.1 cps from 7.2cps in FY17.
Final fully franked dividend of 1.5 cents per share declared, payable on 17 October 2018.
The Income available from dividends remains attractive for many investors.
We take a look at the best yields on the market and assess what they say about a companyâs prospect.
One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkineâs team of analysts bought you handpicked report for âTop 25 Dividend Stocks For 2018.â
ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.
Click here to get your free report.
Disclaimer
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.
